Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.76 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.70 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.70 |
| ▸ | PREP | P48147 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704229 | 0.95 | DPP4 (0.69) | DPP4DPP7DPP8 | |
| SCHEMBL1614514 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL4966643 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL6596978 | 0.83 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL220478 | 0.82 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL6584388 | 0.82 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL29416829 | 0.82 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL160102 | 0.82 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356225 | 0.82 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL6597475 | 0.82 | DPP4 (0.98) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| EP-1671649-B1 | Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure | TAKEDA PHARMACEUTICAL (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20070072810-A1 | Agent for treating diabetes | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20060177509-A1 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1671649-A1 | REMEDY FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20060039974-A1 | Sustained release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1537880-A1 | SUSTAINED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005025554-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072810-A1 | Agent for treating diabetes | IAPP, DPP4, GLP1R | DPP4 2/4885DPP7 5/4885DPP8 7/4885 |
| US-20060039974-A1 | Sustained release preparation | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 5/4885 |
| US-20060177509-A1 | Controlled release composition | ATP6AP1, NSF, ATP6V1G1 | DPP4 2445/4885DPP7 2048/4885DPP8 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.